Cite Score:
1.77
ELSEVIER SCOPUS

17?-estradiol-mediated elevation of peripheral white blood cell count observed during estramustine phosphate therapy for prostate cancer

AUTHORS

Motofumi Suzuki 1 , * , Tetsuya Fujimura 2 , Hiroshi Fukuhara 2 , Yutaka Enomoto 2 , Hiroaki Nishimatsu 2 , Akira Ishikawa 2 , Haruki Kume 2 , Yukio Homma 2 , Tadaichi Kitamura 2

AUTHORS INFORMATION

1 Department of Urology, Graduate School of Medicine, The University of Tokyo, suzukim-uro@h.u-tokyo.ac.jp, Japan

2 Department of Urology, Graduate School of Medicine, The University of Tokyo, Japan

How to Cite: Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, et al. 17?-estradiol-mediated elevation of peripheral white blood cell count observed during estramustine phosphate therapy for prostate cancer, Int J Endocrinol Metab. Online ahead of Print ; 9(4):347-351. doi: 10.5812/Kowsar.1726913X.2246.

ARTICLE INFORMATION

International Journal of Endocrinology and Metabolism: 9 (4); 347-351
Article Type: Original Article
Received: July 3, 2011
Accepted: August 9, 2011
Crossmark

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: In 1983, Daponte et al. first reported an increase in the peripheral white blood cell (WBCs) counts of prostate cancer patients treated with estramustine phosphate (EMP) therapy.
Objectives: In order to confirm Daponte’s observation, we reviewed the clinical data of prostate cancer patients treated with EMP. We also examined the association between WBC counts and 17β-estradiol levels throughout the duration of the EMP therapy.
Patients and Methods: The study population comprised of 66 prostate cancer patients who were being treated with EMP. The complete blood count with a differential WBC count and the levels of serum 17β-estradiol and C-reactive protein measured during the therapy were compared with the baseline levels. The correlation between serum 17β-estradiol level and WBC count was calculated using the Pearson correlation test.
Results: We observed that the total WBC and the neutrophil counts were significantly elevated during the therapy. The serum 17β-estradiol level significantly correlated with the WBC count (r2 = 0.031, P = 0.002). The granulocyte colony-stimulating factor levels measured during therapy were approximately 2-fold higher than the upper limit and decreased after cessation of the treatment (P = 0.037).
Conclusions: We successfully confirmed Daponte’s observation. The increase in WBC counts was possibly attributable to elevated serum 17β-estradiol levels.


  • Implication for health policy/practice/research/medical education:
    Nonphysiological high-dose exposure of 17β-estradiol for prostate cancer patients resulted in significant elevation of neutrophil counts.
  • Please cite this paper as:
    Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A, et al. 17β-Estradiol-Mediated Elevation of Peripheral White Blood Cell Count During Estramustine Phosphate Therapy for Prostate Cancer. Int J Endocrinol Metab. 2011; 9(4):347-51. DOI: 10.5812/Kowsar.1726913X.2246

Copyright © 2012 Kowsar M. P. Co. All rights reserved.


Keywords

Estramustine Prostatic Neoplasms Leukocyte Count Neutrophils Estradiol

© 0, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: